VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.
Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers. Mol Cancer Ther. 2021 10; 20(10):1769-1776.
View in:
PubMed
subject areas
Animals
Humans
Mutation
Neoplasms
Oncogene Proteins, Fusion
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-ret
authors with profiles
GILBERT COTE
VIVEK SUBBIAH